Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Will Pursue Longer Follow-Up For Pediatric Studies, Murphy Says

Executive Summary

FDA plans to require longer follow-up for pediatric studies, CDER Associate Director of Pediatrics Dianne Murphy, MD, told the FDA Anti-Infective Drugs Advisory Committee/Pediatric Subcommittee April 23.

You may also be interested in...



PEG-Intron/Ribavirin Pediatric Responder Studies Address Safety Concerns

PEG-Intron/ribavirin combination studies in children with hepatitis C should consider enrolling only early responders to therapy to minimize adverse events, committee member Robert Fink, MD, Children's National Medical Center, suggested at an April 23 meeting of FDA's Anti-Infective Drugs Advisory Committee/Pediatric Subcommittee.

PEG-Intron/Ribavirin Pediatric Responder Studies Address Safety Concerns

PEG-Intron/ribavirin combination studies in children with hepatitis C should consider enrolling only early responders to therapy to minimize adverse events, committee member Robert Fink, MD, Children's National Medical Center, suggested at an April 23 meeting of FDA's Anti-Infective Drugs Advisory Committee/Pediatric Subcommittee.

Postmarketing Study Status Will Be Defined By Trial Making Least Progress

The overall status of a company's postmarketing commitment for a product will be defined by the study which has made the least progress, an FDA draft guidance states.

UsernamePublicRestriction

Register

PS037792

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel